APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
03 nov. 2022 03h00 HE
|
invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
26 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability...
Cocrystal Pharma to Present at the LD Micro Main Event XV
19 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral...
Pfizer und BioNTech geben frühe positive Daten aus klinischer Studie mit an Omikron BA.4/BA.5 angepasstem bivalenten Auffrischungsimpfstoff bei Personen ab 18 Jahren bekannt
13 oct. 2022 06h45 HE
|
BioNTech SE
Seren von Probandinnen und Probanden, die sieben Tage nach Verabreichung einer 30-µg-Auffrischungsimpfung mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff entnommen wurden,...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
13 oct. 2022 06h45 HE
|
BioNTech SE
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in the Omicron BA.4/BA.5...
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
12 oct. 2022 08h00 HE
|
Codiak BioSciences, Inc.
– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc....
Imunon Reports Partial Results from Ongoing Non-human Primate Study
03 oct. 2022 08h00 HE
|
Imunon, Inc.
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Pfizer und BioNTech reichen Antrag auf Notfallzulassung für Auffrischungsimpfung mit einem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Kinder von 5 bis 11 Jahren bei der FDA ein
26 sept. 2022 06h45 HE
|
BioNTech SE
NEW YORK und MAINZ, Deutschland, 26. September 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass sie bei der US-amerikanischen...
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
26 sept. 2022 06h45 HE
|
BioNTech SE
NEW YORK and MAINZ, GERMANY, September 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...